To obtain a Fas ligand solubilization inhibitor which contains specific compounds a part of which is novel, have an inhibitory activity against matrix metalloprotease and are useful in prevention and treatment for hepatitis, GVHD, AIDS or some kinds of autoimmune diseases.
A matrix metalloprotease inhibitory compound, particularly of formula I [Q is formula II (R6 is H, OH, an alkoxy), formula III (R7 is H, OH, methoxy); A is N-hydroxyaminocarbonyl, carboxyl; R1 is H, amino, an alkoxy, an aryl; R2 is H, an alkyl, an alkenyl] or its pharmaceutically permissible salt is used. Among the compounds of formula I, the compound of formula IV (R11 is a 1-6C alkyl, THN is 5,6,7,8-tetrahydro-1-naphthyl, 5,6,7,8-tetrahydro-2- naphthyl) and its salt are unknown. This drug is effective for treatment and prevention for diseases particularly caused by excessive activation of T-cells.
YAKIDA HIDEO
OKUMURA YASUSHI
HIRAYAMA RYOICHI
YAMAMOTO MINORU
EBATA TOMOHIKO
OMOTO HIROSHI
IKEDA SHOJI
YOSHINO KOICHIRO
